Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.

Frontiers in immunology - 1 Jan 2021

Ding Chengchao, Patel Darshit, Ma Yunjing, Mann Jamie F S, Wu Jianjun, Gao Yong

Abstract excerpt

Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AIDS Vaccines
Share to Broadly Neutralizing Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to env Gene Products, Human Immunodeficiency Virus

Share to Genes, env

Share to HIV Antibodies

Share to Immunity, Humoral

Share to Immunization, Passive

Share to Models, Immunological

Source

Open in PubMed Open full text

Identifiers

PMID: 34354709
DOI: 10.3389/fimmu.2021.697683
PMCID: PMC8329590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.PMID 34354709Read ↗

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune ResponseSemantic proximity Read ↗

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and PreventionSemantic proximity Read ↗

Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.Semantic proximity Read ↗

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.Semantic proximity Read ↗

Harnessing the protective potential of HIV-1 neutralizing antibodiesSemantic proximity Read ↗

Broadly Neutralizing Antibodies for HIV EradicationSemantic proximity Read ↗

Progress toward active or passive HIV-1 vaccination.Semantic proximity Read ↗

<scp>HIV</scp>‐1 neutralizing antibodies: understanding nature's pathwaysSemantic proximity Read ↗

Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.Semantic proximity Read ↗

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.Semantic proximity Read ↗

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>Semantic proximity Read ↗

Antibodies Targeting the Envelope of HIV-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.